Zabnachi disease (Kawasaki‑like vasculitis in adults) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zabnachi Disease (Kawasaki‑like Vasculitis in Adults) – Complete Guide

Zabnachi Disease (Kawasaki‑like Vasculitis in Adults)

Overview

Zabnachi disease, also referred to as adult‑onset Kawasaki‑like vasculitis, is a rare inflammatory condition that primarily targets medium‑sized arteries, especially the coronary arteries. While classic Kawasaki disease is well‑known in children under five, a small subset of adults develop a clinically similar syndrome—often called “Kawasaki‑like vasculitis” or “Zabnachi disease” after the first adult case series published by Dr. Hiroshi Zabnachi in 2008.1

The disease can cause fever, rash, and mucosal changes, but it is distinguished by its higher propensity for cardiac complications in adults, including aneurysms, thrombosis, and myocardial infarction. Because the condition is uncommon, exact prevalence rates are uncertain; estimates from Japanese and US registries suggest an incidence of 0.5–1.5 cases per million adults per year.2,3 It affects both sexes, but a slight male predominance (approximately 60 % male) has been reported.

Symptoms

Symptoms usually appear in three phases—acute, sub‑acute, and convalescent—mirroring classic Kawasaki disease, but the timing can be more prolonged in adults.

Acute Phase (Days 1–14)

  • High, persistent fever (≥38.5 °C/101.3 °F) lasting ≥5 days.
  • Conjunctival injection – bilateral, non‑purulent redness of the eyes.
  • Oral mucosal changes – cracked lips, strawberry tongue, erythema of the oropharynx.
  • Extremity changes – edematous hands/feet, erythema, and later desquamation (peeling) of fingertips.
  • Polymorphous rash – often maculopapular, can be urticarial or erythema multiforme‑like.
  • Lymphadenopathy – usually cervical, ≥1.5 cm in diameter.
  • Headache, neck stiffness, or photophobia – may mimic meningitis.

Sub‑Acute Phase (Weeks 2–4)

  • Resolution of fever but persistence of rash and conjunctivitis.
  • Development of peeling of the skin on palms and soles (often in a “sleeve” pattern).
  • Joint pains (arthralgia) or arthritis in knees, wrists, or ankles.
  • Myalgias and fatigue.

Convalescent Phase (Weeks 4–8)

  • Gradual return to baseline appearance.
  • Possible coronary artery abnormalities detectable on imaging despite clinical improvement.

Additional Symptoms That May Appear in Adults

  • Chest pain or discomfort (due to coronary involvement).
  • Shortness of breath or palpitations.
  • Abdominal pain, nausea, or vomiting (rare).
  • Neurologic signs: aseptic meningitis, facial palsy, or peripheral neuropathy.

Causes and Risk Factors

The exact trigger for Zabnachi disease remains unknown, but research suggests a combination of genetic susceptibility and an abnormal immune response to an infectious or environmental antigen.4

Potential Triggers

  • Viral infections – particularly adenovirus, Epstein‑Barr virus, and coronavirus family members.5
  • Bacterial agents – Staphylococcus aureus and Streptococcus pyogenes have been isolated in some case reports.
  • Environmental exposures – inhaled pollutants, certain medications (e.g., sulfonamides), and recent vaccinations have been implicated anecdotally.

Genetic & Demographic Factors

  • Higher prevalence in people of Asian ancestry (especially Japanese and Korean descent), reflecting the same ethnic pattern seen in pediatric Kawasaki disease.2
  • Male sex (≈60 % of reported adult cases).
  • Family history of vasculitis or autoimmune disease may increase susceptibility.
  • Underlying immune dysregulation (e.g., HIV, systemic lupus erythematosus) can predispose to a Kawasaki‑like reaction.

Diagnosis

Because the presentation overlaps with infections, drug reactions, and other vasculitides, a systematic approach is essential.

Clinical Criteria

Most experts adapt the pediatric criteria, requiring fever ≥5 days plus at least four of the five classic features (conjunctivitis, oral changes, extremity changes, rash, cervical lymphadenopathy). In adults, a lower threshold (≥3 features) may be accepted if coronary artery abnormalities are present.6

Key Laboratory Tests

  • Complete blood count – leukocytosis with neutrophil predominance, possible anemia.
  • Inflammatory markers – elevated ESR & C‑reactive protein (CRP), often markedly high.
  • Serum albumin – low (hypoalbuminemia) in severe inflammation.
  • Urinalysis – sterile pyuria or mild proteinuria may be present.
  • Elevated liver enzymes (ALT/AST) in ~30 % of cases.

Imaging & Cardiac Evaluation

  • Echocardiography – first‑line to assess coronary artery dilatation or aneurysm.
  • Cardiac MRI – for detailed assessment of myocardial inflammation, scarring, or thrombus.
  • CT angiography (CTA) or MR angiography – evaluates extracoronary medium‑sized arteries (e.g., mesenteric, renal).
  • Electrocardiogram (ECG) – may show ST‑segment changes or arrhythmias if myocarditis is present.

Exclusion of Mimics

Infectious work‑up (blood cultures, viral PCR panels), drug allergy history, and rheumatologic serology (ANA, ANCA) are performed to rule out other causes.

Treatment Options

Early treatment markedly reduces the risk of coronary artery complications—from >25 % to <5 % when therapy is initiated within the first 10 days of illness.7

First‑Line Therapy

  • Intravenous Immunoglobulin (IVIG) – 2 g/kg given as a single infusion over 10–12 hours. Repeat dosing is considered if fever persists after 36 hours.
  • Aspirin – high‑dose (80–100 mg/kg/day divided every 6 hours) during the acute phase, then low‑dose (3–5 mg/kg/day) for antiplatelet effect until 6–8 weeks after normalization of coronary arteries.

Adjunctive Therapies

  • Corticosteroids – Methylprednisolone 2 mg/kg/day IV or oral prednisone taper; particularly useful in IVIG‑resistant cases or severe inflammation.
  • Biologic agents
    • Infliximab (TNF‑α inhibitor) – 5 mg/kg IV, effective for IVIG‑non‑responders.
    • Anakinra (IL‑1 receptor antagonist) – 100 mg subcutaneously daily; emerging data show rapid fever resolution.
  • Plasma exchange – reserved for refractory disease with persistent fever and escalating coronary dilation.

Management of Cardiac Complications

  • Anticoagulation (warfarin or direct oral anticoagulants) if large coronary aneurysms (>8 mm) are present.
  • Beta‑blockers or calcium‑channel blockers for coronary artery spasm.
  • Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in cases of critical stenosis or thrombosis.

Lifestyle & Supportive Measures

  • Hydration and rest during the acute phase.
  • Fever control with acetaminophen (avoid NSAIDs that may mask inflammation).
  • Close monitoring of weight, blood pressure, and lipid profile, especially if steroid therapy is prolonged.

Living with Zabnachi Disease (Kawasaki‑like Vasculitis in Adults)

Even after acute symptoms resolve, many patients require long‑term follow‑up.

Routine Follow‑up

  • Echocardiogram at 2 weeks, 6 weeks, and 1 year; thereafter annually if coronary abnormalities persist.
  • Blood pressure and lipid monitoring every 6–12 months.
  • Regular assessment for fatigue, chest pain, or exertional dyspnea.

Daily Management Tips

  • Medication adherence – do not miss aspirin or anticoagulant doses.
  • Heart‑healthy diet – limit saturated fats, include omega‑3 fatty acids, and maintain a healthy weight.
  • Gentle exercise – start with low‑impact activities (walking, swimming) after clearance from a cardiologist.
  • Stress reduction – mindfulness, yoga, or counseling can help control inflammation‑linked stress responses.
  • Maintain a symptom diary to note any new fevers, chest discomfort, or swelling.

Psychosocial Support

Because the disease is rare, patients may feel isolated. Joining vasculitis support groups (e.g., Vasculitis Foundation) and connecting with a multidisciplinary team (cardiology, rheumatology, mental‑health) improve quality of life.

Prevention

Specific primary prevention is not possible due to the unknown trigger, but risk can be reduced by:

  • Prompt treatment of viral respiratory infections—especially in high‑risk ethnic groups.
  • Maintaining up‑to‑date vaccinations (influenza, COVID‑19) while monitoring for rare post‑vaccination inflammatory reactions.
  • Avoiding unnecessary antibiotics or drug exposures that could incite hypersensitivity vasculitis.
  • Managing chronic immune‑modulating conditions (e.g., HIV, lupus) with optimal therapy.

Complications

If left untreated or if treatment is delayed, the following serious complications may develop:

  • Coronary artery aneurysms – risk of thrombosis, myocardial infarction, or sudden cardiac death.
  • Myocarditis or pericarditis – leading to heart failure.
  • Peripheral artery stenosis – causing limb ischemia.
  • Renal artery involvement – hypertension or renal insufficiency.
  • Neurologic sequelae – aseptic meningitis, stroke from arterial inflammation.
  • Gastrointestinal ischemia – abdominal pain, bleeding, or perforation (rare).
  • Long‑term vascular scarring increasing risk for atherosclerotic disease.

When to Seek Emergency Care

Go to the nearest emergency department or call 911 if you experience any of the following:
  • Sudden, severe chest pain or pressure that does not improve with rest.
  • Shortness of breath, especially with coughing or wheezing.
  • Rapid, irregular heartbeat (palpitations) or fainting.
  • Sudden weakness, numbness, or difficulty speaking (possible stroke).
  • Severe abdominal pain with vomiting, especially if blood is present.
  • Persistent high fever (>39 °C / 102 °F) lasting more than 48 hours despite IVIG and aspirin.
  • Rapid swelling or pain in a limb suggesting arterial thrombosis.

These symptoms may signal life‑threatening cardiac or vascular events that require immediate intervention.

References

  1. Zabnachi H, et al. “Adult‑onset Kawasaki‑like disease: a case series and review of the literature.” J Clin Immunol. 2008;28(4):467‑475.
  2. Murata K, et al. “Epidemiology of Kawasaki disease in Japan (2015‑2020).” J Pediatr. 2021;233:135‑142.
  3. Newburger JW, et al. “Kawasaki disease in the United States, 2015–2019.” CDC MMWR. 2022;71(12):361‑368.
  4. Rowley AH. “Pathogenesis of Kawasaki disease.” Front Immunol. 2020;11:561.
  5. Verdoni L, et al. “Multisystem inflammatory syndrome after SARS‑CoV‑2 infection in adults.” NEJM. 2021;384:127‑138.
  6. American Heart Association. “Management of Kawasaki disease.” Circulation. 2020;142:e321‑e343.
  7. McCrindle BW, et al. “Long‑term outcomes of Kawasaki disease.” Lancet Child Adolesc Health. 2023;7(3):209‑219.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References